<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02500225</url>
  </required_header>
  <id_info>
    <org_study_id>Ulku 1</org_study_id>
    <nct_id>NCT02500225</nct_id>
  </id_info>
  <brief_title>Comparison the Effects of Etomidate and Sevoflurane During Electroconvulsive Therapy</brief_title>
  <official_title>Ulku Ozgul, Associate Professor, Inonu University, Department of Anesthesiology and Reanimation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inonu University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inonu University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study was to investigate the effects of etomidate or sevoflurane used in
      electroconvulsive therapy (ECT) on duration of seizure, hemodynamic response and recovery
      profiles.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Twenty-five patients will be a total of 150 ECT treatments in this prospective,
      double-blinded, crossover study. Each patient will receive either 0.2 mg/kg etomidate (Group
      1) or 8% sevoflurane (Group 2) in 100% oxygen at 6 L/min fresh gas flow until loss of
      consciousness for their initial electroconvulsive therapy session. In subsequent sessions,
      patients will receive the alternative sevoflurane concentration and then alternated between
      doses until the sixth session. Muscle paralysis will achieve with 1 mg/kg succinylcholine.
      Motor (EMG) and electroencephalography seizure duration (EEG), heart rate (HR) and mean
      arterial pressure (MAP) values, and recovery times will recorde.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Motor (EMG) seizure duration</measure>
    <time_frame>intraoperative</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>electroencephalography (EEG) seizure duration</measure>
    <time_frame>intraoperative</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>heart rate (HR),</measure>
    <time_frame>(approximately 5 minutes for all measurements) prior to the seizure, after the anesthetic induction, and following the ECT session at 1 minute, 3 minutes, and 10 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean arterial pressure (MAP)</measure>
    <time_frame>(approximately 5 minutes for all measurements) prior to the seizure, after the anesthetic induction, and following the ECT session at 1 minute, 3 minutes, and 10 minutes</time_frame>
    <description>MAP will be measured by a blood pressure cuff</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>recovery times</measure>
    <time_frame>(approximately 5 minutes for all measurements) prior to the seizure, after the anesthetic induction, and following the ECT session at 1 minute, 3 minutes, and 10 minutes</time_frame>
    <description>Recovery times will be assessed with spontaneous breathing, eye opening, obeying commands times</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Anesthesia</condition>
  <condition>ECT</condition>
  <arm_group>
    <arm_group_label>Etomidate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.2 mg/kg etomidate during anesthesia induction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>8% sevoflurane</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sevoflurane 8% concentration during anesthesia induction</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etomidate</intervention_name>
    <description>0.2 mg/kg etomidate</description>
    <arm_group_label>Etomidate</arm_group_label>
    <arm_group_label>8% sevoflurane</arm_group_label>
    <other_name>Hypnomidate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <description>8% Sevoflurane</description>
    <arm_group_label>Etomidate</arm_group_label>
    <arm_group_label>8% sevoflurane</arm_group_label>
    <other_name>Sevorane</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Study include 25 patients of American Society of Anesthesiologists (ASA) physical
             status I-II aged between 18-60 years who schedule for ECT sessions under general
             anesthesia

        Exclusion Criteria:

          -  Pregnancy

          -  Cerebrovascular disease

          -  Epilepsy

          -  Unstable cardiovascular disease

          -  Chronic obstructive pulmonary disease; and

          -  Renal or hepatic failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulku Ozgul, MD</last_name>
    <role>Study Director</role>
    <affiliation>Inonu University School of Medicine</affiliation>
  </overall_official>
  <results_reference>
    <citation>Janouschek H, Nickl-Jockschat T, Haeck M, Gillmann B, Grözinger M. Comparison of methohexital and etomidate as anesthetic agents for electroconvulsive therapy in affective and psychotic disorders. J Psychiatr Res. 2013 May;47(5):686-93. doi: 10.1016/j.jpsychires.2012.12.019. Epub 2013 Feb 9.</citation>
    <PMID>23399487</PMID>
  </results_reference>
  <results_reference>
    <citation>Toprak HI, Gedik E, Begeç Z, Oztürk E, Kaya B, Ersoy MO. Sevoflurane as an alternative anaesthetic for electroconvulsive therapy. J ECT. 2005 Jun;21(2):108-10.</citation>
    <PMID>15905753</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2015</study_first_submitted>
  <study_first_submitted_qc>July 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2015</study_first_posted>
  <last_update_submitted>January 24, 2017</last_update_submitted>
  <last_update_submitted_qc>January 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Inonu University</investigator_affiliation>
    <investigator_full_name>Ülkü Özgül</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Etomidate</keyword>
  <keyword>Sevoflurane</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sevoflurane</mesh_term>
    <mesh_term>Etomidate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

